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 This literature review summarizes the biological concept behind cancer 
and focuses on the use of PD-1 in tumors as a way of immune evasion as well as 
the use of PD-1/PD-L1 blockade as an innovative target for immunotherapy. 
Cancer arises from mutagenic events resulting in the presence of abnormal cells 
and uncontrollable cell proliferation. It is able to evade immune activity through 
many methods of immune evasion, one of which is the PD-1/PD-L1 blockade. 
Normally PD-1 binds to PD-L1 to dampen the immune response after activation 
and cancer is able to take advantage of this immune homeostasis pathway to 
prevent immune attack. It has been shown that inhibition of the PD-1/PD-L1 
blockade can act to block the interaction between PD-1 and PD-L1, thus allowing 
the T cells of the immune system to activate and attack the cancer. This has led 
to the invention of PD-1/PD-L1 checkpoint inhibitors, with currently 6 approved by 
the FDA for the treatment of a wide spectrum of cancers. The discovery of PD-
1/PD-L1 blockade has made a leap of advancements in cancer immunotherapy; 
however, as the number of therapies is expected to rise in the future, several 
 v 
issues remain that require further investigation to optimize the potential of PD-
1/PD-L1 inhibitors. Specifically, mechanisms of resistance, mechanisms behind 
non-immunogenic tumors, and immune-related adverse events are areas that 
warrant further examination in order to fully maximize the benefits and minimize 
the risks of PD-1/PD-L1 inhibitors. The bispecific combination molecule 
cotargeting PD-1/PD-L1 could be a possible alternative therapeutic approach 
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INTRODUCTION 
In the United States, cancer is responsible for 21% of all deaths (Siegel, Miller, 
Fuchs, Jemal, 2021) and is a major public health problem in the rest of the world. 
In males, the most common cancers accounting for 46% of all diagnoses include 
prostate and lung, with prostate alone taking 26% of all diagnoses (Table 1). In 
females, breast, lung, and colon/rectal cancers account for 50% of new 
diagnoses, with breast cancer accounting for 30%. Excluding non-melanoma skin 
cancers and other non-invasive cancers, in 2019, approximately 1.7 million 
cancers were diagnosed and nearly 600,000 people died (Siegel, Miller, Fuchs, 
Jemal, 2021). In 2019, the most common deaths from cancer are lung cancer, 
colorectal cancer, stomach cancer, liver cancer, and breast cancer. Estimates 
are that in 2021, 1.9 million new cases of cancer and 608,570 deaths will occur in 
the United States (Siegel, Miller, Fuchs, Jemal, 2021). Although various methods 
such as screening and early prevention have resulted in a drop in cancer 






Table 1. Estimated new cancer cases and deaths in the US in 2021. (Siegel, 
Miller, Fuchs, Jemal, 2021)  
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Cancer is a biological disease arising from a complex interaction of both 
environmental and genetic factors that results in tumorigenesis. This name is 
given to a collection of diseases (~200) with one common factor: some of the 
body’s cells begin to grow abnormally with the potential to spread or invade the 
surrounding tissues and even the rest of the body. Cancer can originate from 
anywhere in the human body, which is made up of trillions of cells, all of which 
grow, divide, and die in a controlled way. Examples of this include organs with 
continued cell renewal such as your skin, the gut, or blood cells; old and 
damaged cells undergoing cell death to be replaced with new cells; tissue repair 
during the wound healing process; and embryonic development. This normally 
orderly and well-regulated process can go wrong if the genomic DNA of a cell 
becomes damaged or changed. The change in genetic material may produce 
mutations that interrupt the control over normal cell growth, division, and 
apoptosis (cell death). Under these conditions, three consequences happen to 
your cells. They do not undergo apoptosis when they should; they do not 
terminally differentiate and continue to divide; and new cells will form where they 
are not needed. This surplus of cells will result in the formation of a mass of 
tissue called a tumor. These tumors are malignant, meaning that they are able to 
invade neighboring tissue and spread. In addition, as these tumors continue to 
grow, cancer cells within the tumor can break off and enter the blood or lymphatic 
vessels, travel to distant locations in the body, and then leave the circulation to 
implant a new tumor.  
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Our Immune System 
Our immune system is composed of two portions, the innate and adaptive 
systems, which work together to perform a variety of functions including 
recognizing, destroying, and clearing the body of a diversity of aggressions, 
infectious and non-infectious, exogenous and endogenous. It can be imagined 
that early and efficient detection of such invaders, as well as the quick 
recruitment of defense mechanisms are vital to stop the infection locally and 
neutralize the threat. This responsibility falls upon the innate immune system, 
composed of cytokines, interferons, and leukocytes including neutrophils, 
macrophages, natural killer (NK) cells, and granulocytes, which work together to 
eliminate the foreign pathogen. Normally, the mechanisms of the innate immune 
system are enough to disperse the threat without requiring the help of the 
adaptive immune system, which takes more time to activate in part due to the 
requirements for T lymphocyte activation and maturation. The adaptive immune 
system, a major focus of this thesis, includes B cells and T cells and is 
responsible for recognizing “non-self” antigens and generating responses that 
are designed to maximally eliminate specific pathogens or pathogen-infected 
cells. The adaptive immune system starts with the display of an antigen on the 
surface of an antigen presenting cell (APC) and activates T cells. APCs are 
defined as any cell with the ability to process and present antigens on the cell 
membrane, but the most commonly used APCs in the body are dendritic cells, 
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macrophages, and B cells. APCs internalize antigens to form a peptide-MHC 
complex, which requires the degradation of a protein antigen into peptides and 
are displayed on a major histocompatibility complex (MHC) molecule. MHC 
molecules can be split into Class I or Class II. Class I MHC molecules present 
endogenous antigens found in the cytoplasm, while Class II MHC molecules 
present exogenous antigens that are internalized. T cells are not only activated 
by the MHCs on the APCs, but also use these complexes to recognize and 
attack foreign cells.  
T cells are born in the marrow, but then migrate to the thymus for T cell 
development. These cells are initially referred to as CD4/CD8 double negative 
(DN) thymocytes, cells that express neither CD4 nor CD8 (Scollay, Bartlett, 
Shortman, 1984). These DN lymphocytes then migrate from the corticomedullary 
junction to the cortex and subsequently transform into CD4/CD8 double-positive 
(DP) thymocytes (Jin et al., 2012). DP thymocytes express T-cell receptors 
(TCR), the majority of which are of the αβ variety. These TCRs are expressed on 
the cell surface and interact with peptide-MHC complexes to differentiate into 
mature T cells. Through the process of positive selection in the thymic cortex, T 
cells differentiate into either T helper cells (CD4+CD8-) or cytotoxic T cells 
(CD8+CD4-) through the recognition of and binding to class II MHC molecules or 
class I MHC molecules, respectively (Maruŝić-Galesić et al., 1988). Not only 
should T cells be able to recognize foreign antigens, but it is also important for 
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the immune system to have the ability to differentiate self from non-self. As such, 
after T cells are selected into either CD4+ or CD8+ single positive thymocytes, 
they migrate to the thymic medulla and undergo negative selection for self-
reactive thymocytes to establish self-tolerance (Jin et al., 2012). After completing 
T cell development, mature thymocytes emerge from the thymus through the 
perivascular space and migrate to peripheral lymphoid organs. There, they join 
the rest of the immune system in one of its roles to identify and eliminate tumors.  
 
From normal cells to cancer cells 
Cancer cells differ from normal cells in many ways and these differences are 
what allow them to grow uncontrollably and become invasive. An important 
difference is that cancer cells are less specialized than normal cells. Specifically, 
while a normal cell will mature into a distinct cell type with a specific function, 
cancer cells do not, allowing them to continuously divide. In addition, cancer cells 
are able to bypass signals that inform cells to stop dividing during the cell cycle. 
But how does a normal cell become malignant?  
To answer this question, we require a brief overview of the cell cycle. The cell 
cycle involves four phases: G1, S, G2, and M. During the G1 phase, the cell 
undergoes hypertrophy, a growth in cell size. It also monitors the availability of 
growth factors, nutrients, and amino acids, and uses this information to ensure 
that the conditions are appropriate to support DNA replication and whether there 
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is space to grow. As a result, this phase is a restriction point in the cell cycle. 
Once the cell passes this phase, it is past the “point of no return” and will 
proceed to cell division. The S phase is the point in the cell cycle where DNA 
replication occurs. Although the processes that occur in this phase are tightly 
regulated to ensure accuracy, there is still the possibility of errors, resulting in 
genomic DNA changes that can lead to cancer. In the G2 phase, the cell 
continues to grow in size and begins preparing for mitosis (cell division). And 
finally, in the M phase, the cell undergoes mitosis and divides into two identical 
daughter cells.  
In all human cancers, loss of the restriction checkpoint at between the G1 and S 
phase is a distinctive feature. Numerous mutations enable cancer cells to 
continuously pass through G1/S, even when they should not be proliferating. So 
how is the G1/S transition normally regulated? On the cell surface, we can find 
receptors for growth factors such as endothelial growth factor receptor (EGFR) 
and vascular endothelial growth factor receptors (VEGFR). The ligands of these 
growth factors bind to extracellular regions of receptor tyrosine kinases (RTKs), 
which are activated following ligand-induced receptor dimerization or 
oligomerization. In RTKs, the conformational changes following activation allow 
for self-phosphorylation and enables RTKs to recruit and activate a large variety 
of downstream signaling pathways such as MAPK and PI3K (Du, Lovely, 2018). 
These pathways contain proteins with Src homology-2 (SH2) or phosphotyrosine 
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binding (PTB) domains. Binding of different domain containing proteins leads to 
the activation of different signaling cascades, which in turn lead to transcription of 
genes important for growth. One of these genes encodes for cyclin D, a protein 
involved in the G1/S transition. Cyclin D binds and activates cyclin-dependent 
kinases 4 and 6 (CDK4/6). The activated CDK4/6 complexes phosphorylate the 
retinoblastoma tumor suppressor protein (pRb), which governs the passage of 
cells through the G1/S transition in the absence of proper mitogenic signals. 
Phosphorylated pRb releases E2F transcription factors and allows for expression 
of genes necessary for S-phase (VanArsdale, Boshoff, Arndt, Abraham, 2015). 
The cell is now committed to cell division; the cell has passed the checkpoint.  
Cancer cells are also able to impact the normal cells and blood vessels 
surrounding them to feed the tumor – this is an area known as the tumor 
microenvironment. This influence can cause the uncontrolled growth that is now 
seen as a hallmark of cancer in blood vessels, promoting tumorigenesis. Under 
normal conditions, blood vessel growth is regulated by the HIF (hypoxia-inducible 
factor) pathway. In the presence of oxygen, otherwise known as normoxia, the 
proline residues of HIF are hydroxylated, allowing HIF to interact with the Von 
Hippel-Lindau protein (pVHL), a tumor suppressor. This interaction between HIF 
and pVHL results in degradation of HIF by ubiquitination (Rahimi, 2012). 
However, in low oxygen (hypoxic) conditions, the pVHL is S-nitrosylated which 
prevents HIF from recognizing and interacting with pVHL, and the degradation of 
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HIF does not occur. This in turn allows HIF to stimulate vascular endothelial 
growth factor (VEGF), leading to angiogenesis as seen in cancer progression 
(Rahimi, 2012). How does the growth of blood vessels allow for tumorigenesis? 
Firstly, tumor associated blood vessels are not normal. They exhibit abnormal 
structure and chaotic organization. Vessel shape can vary from abnormally wide 
and irregular winding shapes to thin compressed channels. The vessels are 
leaky and immature, increasing interstitial fluid pressure and allowing tumor cell 
dissemination, and also have loose cell-to cell interactions that can obstruct 
blood flow (Potente, Gerhardt, Carmeliet, 2011). These abnormalities taken 
together result in impaired oxygen and hypoxic conditions that lead to further 
vessel growth. However, these excess vessels only lead to further 
disorganization as the angiogenesis that results continues to produce abnormal 
vessels, turning into a vicious cycle and forming the hostile tumor 
microenvironment. Experimental evidence for the role of angiogenesis in cancer 
has also been shown. Tumors were subcutaneously implanted into mice and 
tumor growth was followed over time. Before vascularization, these tumors grew 
slowly and the tumor volume increased linearly. However, after vascularization, 
tumor growth was rapid and tumor volume increased exponentially (Weinberg, 
2014).  
Lastly, cancer cells have the ability to evade our immune system, which functions 
to protect our body from infections and other invasions. Although the immune 
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system should normally remove damaged and abnormal cells, such as cancer 
cells, from the body, some cancer cells can “hide” from our immune system, or 
even use the immune system to stay alive and grow. The abnormal tumor cells 
can express antigens not found on normal cells, known as tumor antigens. The 
immune system should recognize these antigens as foreign, or not native to the 
body, and should subsequently activate immune cells to attack the tumor cells. 
These antigens could come from oncogenic viruses like HPV or can be the 
body’s own proteins that normally occur at low levels but are highly expressed in 
tumor cells. Similar as described above, tumor antigens are presented on Class I 
MHC molecules and allows cytotoxic T cells to recognize the tumor cell as 
abnormal (Syn, Teng, Mok, Soo, 2017). However, tumors can evade the immune 
system in several ways. Some tumors have fewer Class I MHC molecules on 
their cell surfaces, thus reducing the chance for detection by cytotoxic T cells 
(Syn, Teng, Mok, Soo, 2017). Other tumors also release cytokines or express 
proteins that inhibit the immune response. For example, secreting TGF-β can 
suppress the activity of macrophages and lymphocytes (Seliger, 2005). Also, the 
increased expression of PD-L1 on tumor cells can shut down the immune 





Molecular structure of PD-1 and PD-L1 
Programed death 1 (PD-1), also known as CD279, is a type I transmembrane 
protein composed of 288 amino acids. PD-1’s structure includes a single N-
terminal extracellular IgV-type domain with 25% sequence similarity to those 
found in the CD28 and CTLA-4 family, a 20-amino acid stalk separating the IgV 
domain from the plasma membrane, a transmembrane domain, and a 
cytoplasmic tail (Lin et al., 2008; Riley 2009). However, PD-1 lacks the cysteine 
residue located proximal to the membrane seen in other family members which is 
essential for homodimerization, so it is believed to exist as a monomer on the cell 
surface (Zak, Kitel, Przetocka et al., 2015). The cytoplasmic tail contains two 
tyrosine-based signaling motifs. One is an immunoreceptor tyrosine-based 
inhibitory motif (ITIM) containing an N-terminal sequence VDYGEL which is 
responsible for recruiting SH2 domain-containing phosphatases. The other is an 
immunoreceptor tyrosine-based switch motif (ITSM) containing a C-terminal 
sequence TEYATI (Boussiotis, Chatterjee, Li, 2015). These two motifs are 
indispensable to the inhibitory function of PD-1 and suggests that PD-1 
negatively regulates T-cell receptor signals. This is consistent with the binding of 
SHP-1 and SHP-2 phosphatases to the cytoplasmic tail upon binding of PD-1 
with its ligand PD-L1 (Figure 1). 
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Programed death ligand 1 (PD-L1), also known as CD274 or B7-H1, is also a 
type I transmembrane protein weighing 40 kDa. It contains an IgC proximal 
domain and an IgV distal domain in its extracellular domain, typical to the B7 
family. Within the IgV domain, PD-L1 has complementary determining-like 
regions (CDRs) that allow it to bind to PD-1 with a 1:1 stoichiometry (Zak, Kitel 
Przetocka et al., 2015). This resembles the binding of an antigen by antibodies 
and T-cell receptors (Lin et al., 2008). PD-L1 also contains a hydrophobic 
transmembrane region followed by a short intracellular region containing motifs 
that transduce survival signals and regulate PD-L1 stability and signal 
transduction (Escors, Gato-Canas, Zuazo et al., 2018).  
 
Expression and distribution of PD-1 and PD-L1 
PD-1 is expressed on activated CD4 and CD8 T cells, B cells, natural killer (NK) 
cells, macrophages, monocytes, and dendritic cells (Lu et al., 2019; Zuazo, Gato-
Cañas, Llorente et al., 2017). PD-1 expression can also be induced in antigen 
presenting cells (APCs), monocytes, B cells, and T cells (Lu, Ni, Liu et al., 2019). 
However, I will mainly be focusing on PD-1 expression on T cells, which can be 
induced by several factors. PD-1 is expressed on CD4-CD8- naïve thymocytes 
and is up-regulated through TCR signaling (Bally, Austin, Boss, 2016). PD-1 
expression can also be increased in TCR-stimulated T cells through TGFβ 
activation (Rekik et al., 2015). Not only that, but the common γ-chain cytokines 
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IL-2, IL-7, IL-15, and IL-21 have also been shown to induce PD-1 expression on 
T cells (Kinter et al., 2008). NFATc1 is a transcription factor that is activated 
through the initiation of a signaling pathway by TCR stimulation that promotes 
PD-1 expression (Bally, Austin, Boss, 2016). Other established transcriptional 
activators of PD-1 include Foxo1 and Notch while T-bet is a known transcriptional 
inhibitor of PD-1. In a chronically infected mice model, high PD-1 expression on T 
cells can result in the appearance of “exhausted” T cells, leading to decreased 
cytokine secretion and cytolytic activity (Barber, Wherry, Masopust et al., 2006). 
However, exhausted T cells have also been observed in patient with cancer, 
suggesting that high expression of PD-1 in T cells in the tumor microenvironment 
causing T cell exhaustion could lead to the failure of cancer elimination.  
On the other hand, PD-L1 is not only expressed in hematopoietic cells such as T 
cells, B cells, macrophages, and dendritic cells but is also found in some non-
hematopoietic tissues such as heart, liver, eye, muscle, pancreas, skin, vascular 
endothelium, and placental tissues (Qin, Hu, Zhang et al., 2019). The expression 
of PD-L1 in normal tissues seems to suggest that the PD-1/PD-L1 signaling 
pathway has an important role in preventing tissue inflammation and maintaining 
homeostasis in the body. This can be supported by the report of PD-L1 
expression modulation by inflammatory signals from immune cells over the past 
few years. Of note, interferon γ (IFN- γ) which is produced by CD4+ helper T cells 
and CD8+ cytotoxic T cells, is considered one of the most potent inducers of PD-
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L1 expression. However, PD-L1 expression has also been observed to be 
induced on the surface of tumor cells in a variety of solid malignancies such as 
melanoma and carcinomas of the head and neck, pancreas, breast, bladder, 
urothelium, ovary, and lung (Wang, Teng, et al., 2016). This is likely due to the 
inflammation induced by tumor-specific or nonspecific immune cells in the tumor 
microenvironment that have been recruited into the tumor site. It has been shown 
that PD-L1 expression can be induced on tumor cells through two mechanisms, a 
constitutive mechanism and an induced mechanism, both of which require a 
transcription factor, interferon regulatory factor-1 (IRF-1) and IFN-γ stimulation 
(Lee, Jang, Lee et al., 2006). As such, PD-L1 plays a critical role in the 
progression of cancer by a mechanism of immune surveillance evasion. 
 
PROGRAMMED DEATH-1 AND PROGRAMMED DEATH LIGAND-1 IN 
TUMORS 
The introduction of therapeutic antibodies as a way of targeting immune 
checkpoints has greatly changed the treatment landscape of tumors and its 
clinical development has given rise to a new phase in anti-tumor therapy. In 
multiple tumors, these antibodies are able to induce a sustained immune system 
response with significant survival advantages. However, in some tumors, the 
response rate is still low, puzzling researchers. This gives rise to the following 
questions. What differentiates between cancers that allow the immune system to 
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be activated and cancers that can evade immune surveillance even when 
immunotherapy is used? 
“Hot” and “cold” tumors 
The terms “hot” and “cold” are layman’s terms given to describe tumors that are 
immunogenic or non-immunogenic, respectively; that is, whether the immune 
system can infiltrate the tumor. Tumors that are labeled as “hot” are 
immunogenic, meaning they show signs of inflammation that prove the tumor has 
already been infiltrated by T cells that are attacking the tumor. The immune cells 
are able to infiltrate due to the presence of neoantigens, a truly foreign protein 
only found on tumors that is entirely absent from normal tissues. The presence of 
this neoantigen is not only highly immunogenic but allows CD4+ and CD8+ T cells 
to be activated and generate an immune response after they have been 
recognized. However, the constant supply of neoantigens results in a chronic 
activation of T cells, leading them to terminally differentiate into an exhausted 
phase. This state of T cell dysfunction is characterized by poor function and a 
sustained expression of inhibitors such as PD-1, preventing an optimal attack 
against the cancer (Wherry, 2011). Tumors that are labeled as “cold” are non-
immunogenic and have not been infiltrated by the immune system, suggesting a 
dysfunction in the workings of the immune system. This does not necessarily 
mean a lack of T cells; there could be T cells in the tumor microenvironment but 
are unable to activate within the tumor for one reason or another.  
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A “cold” tumor: Mechanisms of tumor evasion 
There has been an increase into investigation of non-immunogenic tumors as 
immunotherapeutic treatment has become a challenge due to the absence of an 
adaptive immune response. Possible reasons for a lack of T-cell infiltration likely 
involve a defect during the antitumor immune response and can include an 
absence of tumor antigens, a dysfunction in antigen presenting cells (APCs), the 
absence of T cell activation, or a lack of T cell homing to the tumor (Bonaventura, 







Figure 2. Mechanisms to make “cold” tumors “hot”.  
The absence of tumor infiltrate within a non-immunogenic tumor can be due to a 
dysfunction at any step in the antitumor immune response cycle: Lack of tumor 
antigens, a decrease in the number of APCs, absence of T cell activation, or 
impaired trafficking and infiltration into tumors. (Bonaventura, Shekarian, Alcazer 
et al., 2019, adapted from Chen and Mellman, 2013). 
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Tumor antigens are foreign substances produced in tumors that can be released 
into the bloodstream or displayed on the cell surface. The recognition of these 
antigens by CD8+ T cells activates the immune response against cancer. Some 
non-immunogenic tumors have been found to have a lower expression of tumor 
antigens, which could explain the lack of T-cell activation within the tumor 
(Bonaventura, Shekarian, Alcazer et al., 2019). The next step in the antitumor 
immune response involves the presentation of tumor antigens by APCs, which 
allow for the activation of T cells. A study has already shown that the expression 
of antigen presenting cells such as dendritic cells, along with MHCs, are 
correlated with increased T cell infiltration into the tumor (Spranger, Luke, Bao et 
al., 2016). The third step of the antitumor response involves the stimulation and 
activation of T cells after antigen recognition. Naïve T cells require contact with 
mature APCs in order to become primed to recognize tumor antigens 
(Bonaventura, Shekarian, Alcazer et al., 2019). APCs express Pattern 
Recognition Receptors (PRRs) which recognize Pathogen-Associated Molecular 
Patterns (PAMPs) that are required for T cell receptor priming. However, a lack 
of PAMPs results in a lack of competent APCs that leads to the absence of T cell 
help in fighting the tumor. A study has shown that a lack of PRRs on APCs failed 
in antigen presentation and T cell activation, resulting in low T cell infiltrate and a 
lack of antitumor activity in colon and breast cancers (Vacchelli, Ma, Baracco et 
al., 2015). The last step involves T cell trafficking to the tumor, the travel of T 
cells to the site of the tumor in the body. A lack of cytokines or chemokines at the 
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tumor can cause decreased T cell homing to the tumor (Bonaventura, Shekarian, 
Alcazer et al., 2019). The therapeutic approach of PD-1 antibodies or bispecific 
antibodies could help with T cell trafficking by recruiting T cell binding and 
infiltrating into the tumor.  
 
CLINICAL THERAPY USING PD-1/PD-L1 BLOCKADE  
Understanding the different intracellular changes as a result of carcinogenesis 
has resulted in many treatment options including chemotherapy, radiation 
therapy, surgery, and biologic therapy. Biologic therapies for cancer mainly refer 
to immunotherapy, which helps the body’s immune system fight the cancer. 
Immunotherapies include monoclonal antibodies, adoptive therapy, and immune 
checkpoint inhibitors (Farkona, Diamandis, Blasutig, 2016). Monoclonal 
antibodies are artificial immune system proteins that have been designed to bind 
to specific targets on the cancer cells, either to mark them as targets for the 
immune system, or to interrupt the cancer cell’s abnormal function. Adoptive 
therapy is a treatment that can stimulate the natural ability of the T cell to fight 
cancer. Immune cells are taken from the patient’s tumor and selected for the 
ones that are most active. These are modified in the lab to boost their attacking 
ability, expanded through culture, and injected back into the patient’s body 
(Farkona, Diamandis, Blasutig, 2016). Immune checkpoint inhibitors block 
immune checkpoints that are used by the body to regulate our immune response. 
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As cancers can take advantage of these immune checkpoints to evade the 
immune system, blocking these checkpoints using immune checkpoint inhibitors 
can rev up the immune system to fight against the cancer. The discovery of the 
PD-1/PD-L1 gave rise to the possibility of immune checkpoint inhibitors as an 
exciting new category of immunotherapy drugs (Figure 3).  
Figure 3. Mechanism of action of PD-1/PD-L1 inhibitors. PD-1 is expressed 
on a variety of immune cells including activated T cells. Binding of PD-1 to PD-L1 
results in suppression of the immune response and proliferation of T cells. 
Activation of PD-1/PD-L1 signaling pathway is a highly used mechanism by 
which tumors can evade antigen-activated T cell response. Monoclonal antibody 
blockade of this pathway can reverse the inhibition of the immune response, 
activating the antitumor activity of T cells to enhance tumor attack (Gong, 
Chehrazi-Raffle, Reddi et al., 2018).  
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Several initial Phase 1 studies assessing humanized IgG antibodies targeting 
PD-1 and PD-L1 advanced solid tumors soon started and facilitated the 
development and FDA approval of the first PD-1 inhibitors, nivolumab and 
pembrolizumab (Patnaik et al., 2015, Brahmer et al., 2012) (Table 2). Immune 
checkpoint inhibitors have now been approved for treatment in cancers ranging 
from Hodgkin’s lymphoma to non-small cell lung cancer to urothelial bladder 
cancer (Darvin et al., 2018).  
 
 
Table 2. PD-1/PD-L1 inhibitory monoclonal antibodies in clinical 




Melanoma is known as a cancer of the skin and is the most aggressive and 
dangerous form of skin cancer that arises from abnormal melanocytes, the cells 
that produce melanin for the skin. It most often arises from skin areas with 
prolonged sun damage. It is the 6th most common cancer in both men and 
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women (Siegel, Miller, Fuchs, Jemal, 2021). Melanoma is known as a “hot” tumor 
due to the occurrence of T cell infiltration. Although T cells can become activated 
by recognizing melanoma tumor antigens, they still need the ability to infiltrate 
the tumor microenvironment. This prevalence of T cell infiltration has been shown 
to be associated with a good prognosis (Mahmoud, Shields, Makhoul et al., 
2017). Melanoma has also been shown to have a high tumor mutational burden 
(TMB). This means melanoma tumors have a higher number of mutations giving 
rise to new tumor antigens, neoantigens, that are more likely to be recognized by 
the immune system as non-self and thus can activate the immune system 
(Mahmoud, Shields, Makhoul et al., 2017).  
 
Pembrolizumab 
On September 4, 2014, pembrolizumab became the first PD-1 inhibitor to receive 
accelerated approval by the US Food and Drug Administration (FDA) for the 
treatment of melanoma in patients with unresectable or metastatic melanoma 
after receiving ipilimumab which is a CTLA-4 inhibitor or in patients with BRAF 
V600 mutation after treatment with a BRAF inhibitor (Raedler, 2015). 
Pembrolizumab is a high affinity, highly selective humanized IgG4 monoclonal 
antibody that binds to PD-1 and prevents binding with PD-L1 (Patnaik, Kang, 
Rasco et al., 2015). This binding allows the immune system to activate T cells to 
attack tumor cells. Participants for Phase 1 of the KEYNOTE-001 study were 
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chosen randomly to form an international sample and were made up of 173 
patients over 18 years old with unresectable or advanced melanoma who had 
previously failed treatment with at least two doses of ipilimumab (Robert, Ribas, 
Wolchok, Hodi, Hamid, Kefford et al., 2014). Patients were randomly assigned to 
a treatment group of either intravenous pembrolizumab at 2 mg/kg every 3 weeks 
or 10 mg/kg every 3 weeks. The primary endpoint of the study was determining 
overall response rate (ORR) per the guidelines of response evaluation criteria in 
solid tumors (RECIST) 1.1. These guidelines outline a set of rules that define 
tumor response in patients. The ORR was 26% in both the 2mg/kg and 10 mg/kg 
groups, with 21 out of 81 patients in the 2 mg/kg group responding and 20 out of 
76 patients in the 10 mg/kg group responding (Robert, Ribas, Wolchok, Hodi, 
Hamid, Kefford et al., 2014). Drug-related adverse events were reported in 15% 
of patients in the 2 mg/kg group with the most common being fatigue (6%) and 
8% of patients in the 10 mg/kg group with one patient each experiencing 
diarrhea, dyspnea, musculoskeletal pain, rash, and hypoxia (Robert, Ribas, 
Wolchok, Hodi, Hamid, Kefford et al., 2014). 18 months later, a follow-up to 
KEYNOTE-001 for all patients was published. The endpoint of this study was to 
determine antitumor benefit through the measures of progression-free survival 
(PFS) and median overall survival (OS). The PFS at 6 months for treated 
patients was 45% and median OS was 25.9 months with a one-year OS of 69% 
(Ribas, Wolchok, Robert, Kefford, Hamid, Daud et al., 2015). This study 
concluded pembrolizumab to be safe and well-tolerated, with 14% of all patients 
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experiencing drug-related adverse effects and no treatment related deaths 
(Ribas, Wolchok, Robert, Kefford, Hamid, Daud et al., 2015). 
Pembrolizumab received regular approval from the FDA for unresectable and 
advanced melanoma as well as an expanded approval to include previously 
untreated advanced melanoma regardless of the presence of BRAF mutation on 
December 8, 2015, after results from the KEYNOTE-006 trial (Robert, Schachter, 
Long et al., 2015). In this randomized Phase 3 study, 834 patients were randomly 
assigned to receive either intravenous pembrolizumab at 10 mg/kg every 2 
weeks or every 3 weeks or four intravenous doses of ipilimumab at 3 mg/kg 
every 3 weeks (Robert, Schachter, Long et al., 2015). These patients were 18 
years of age or older and had unresectable stage III or IV melanoma with no 
more than one previous treatment with systemic therapy. Primary endpoints were 
PFS and OS with secondary endpoints including ORR, response duration, and 
safety. 6-month PFS for patients who received pembrolizumab every 2 weeks or 
every 3 weeks was 47.3% and 46.4% respectively. 6-month PFS for patients who 
received ipilimumab was 26.5%. Hazard ratios for disease progression for both 
pembrolizumab regimens versus ipilimumab was 0.58 (95% confidence interval 
0.46-0.72 and 0.47-.72 respectively, p<0.001) (Robert, Schachter, Long et al., 
2015). One-year OS in pembrolizumab groups was superior compared to 
ipilimumab as well with 74.1% of patients on the 2-week pembrolizumab and 
68.4% of patients on the 3-week pembrolizumab compared with 58.2% of 
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patients on ipilimumab. The most common drug-related adverse effects in the 
pembrolizumab groups were fatigue, diarrhea, rash, and pruritus while 
ipilimumab patients experienced pruritus, diarrhea, fatigue, and rash (Robert, 
Schachter, Long et al., 2015). Adverse events related to the immune mechanism 
of these treatments were colitis (1.4%) and hepatitis (1.1%) in pembrolizumab 
and colitis (8.2%) in ipilimumab.  
 
Nivolumab 
On December 22, 2014 nivolumab became the second PD-1 targeting therapy 
and was granted accelerated approval by the FDA for second-line treatment in 
patients with unresectable or metastatic melanoma who did not previously 
respond to ipilimumab and in patients with melanoma with BRAF V600 mutations 
who did not respond to ipilimumab or a BRAF inhibitor. Nivolumab is a fully 
humanized IgG4 monoclonal antibody that binds to PD-1, thus blocking its 
interaction with PD-L1. This releases the PD-1 pathway mediated inhibition of the 
immune response, activating the anti-tumor immune response, and shrinking 
tumor size.  
In the randomized, controlled, open-label, Phase 3 CheckMate 037 trial, a total of 
631 patients were screened from 90 sites in over 10 countries. Participants were 
18 years or older and had unresectable stage IIIC or stage IV or metastatic 
melanoma that had progressed after anti-CTLA-4 and/or a BRAF inhibitor 
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(Weber, D’Angelo, Minor et al., 2015). 272 participants were randomly assigned 
intravenous nivolumab 3mg/kg every 2 weeks and 133 participants were 
assigned investigator’s choice of chemotherapy (ICC). Primary endpoints were 
patient proportion who had an ORR and OS. PD-L1 expression was determined 
using PD-L1 IHC staining with positive PD-L1 expression defined as more than 
5% of tumor cells exhibiting positive staining of any intensity in a section 
containing at least 100 evaluable cells (Weber, D’Angelo, Minor et al., 2015). The 
ORR in the nivolumab group was 31.7% compared to 10.6% in the ICC group. In 
patients with confirmed PD-L1 positive expression, ORR was 43.6% in 
participants treated with nivolumab compared to 9.1% in ICC. Grade 3-4 adverse 
events were seen in 9% of nivolumab-treated patients and included increased 
lipase, alanine aminotransferase, anemia, and fatigue. 32% of ICC patients 
experienced Grade 3-4 adverse events such as neutropenia, thrombocytopenia, 
and anemia (Weber, D’Angelo, Minor et al., 2015).  
On October 1, 2015, based on results from the CheckMate 069 trial, nivolumab 
was approved in combination with ipilimumab as a first-line treatment for BRAF 
V600 positive unresectable or metastatic melanoma. This phase 3 double-blind 
study compared four doses of ipilimumab 3 mg/kg in combination with nivolumab 
1 mg/kg or placebo for 3 weeks, followed by nivolumab 3 mg/kg or placebo every 
2 weeks with ipilimumab 3 mg/kg monotherapy every 3 weeks in 142 patients 
with advanced BRAF V600 p positive melanoma (Postow, Chesney, Pavlick et 
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al., 2015). ORR in the patients was 61.1% in the ipilimumab and nivolumab 
combination group compared to 10.8% in the ipilimumab alone group. 
Importantly, complete tumor response, meaning disappearance of all target 
lesions, was noted in 22% of patients in the combination group while none 
occurred in the ipilimumab alone group. Interestingly though, ORR was 
independent of patient PD-L1 tumor expression status. ORR was 58.3% among 
patients with PD-L1 expressing tumors (same criteria for IHC staining as 
mentioned above) compared to 55.4% in patients with PD-L1 negative tumors 
receiving combination regimen (Postow, Chesney, Pavlick et al., 2015). The 
combination group reported more grade 3-4 adverse events than in the 
monotherapy group, 54% to 24% respectively. The most common combination 
therapy-related adverse events were colitis, diarrhea, and increased alanine 
aminotransferase while the most common monotherapy-related adverse events 
were diarrhea and colitis (Postow, Chesney, Pavlick et al., 2015).  
Nivolumab and ipilimumab combination therapy later received expanded 
accelerated approval for unresectable or advanced metastatic melanoma 
patients regardless of BRAF mutational status on January 23, 2016, based on 
results of CheckMate 067 (Larkin, Chiarion-Sileni, Gonzalez et al., 2015). This 
randomized, double-blind, phase 3 trial evaluated nivolumab alone or nivolumab 
combined with ipilimumab versus ipilimumab alone in 945 previously untreated 
patients with unresectable stage III or stage IV melanoma. Patients were 
 29 
randomly assigned to be treated with nivolumab 3 mg/kg every 2 weeks alone, 
nivolumab 1mg/kg in combination with ipilimumab 3 mg/kg every 3 weeks for four 
doses followed by nivolumab 3 mg/kg every 2 weeks, or ipilimumab 3 mg/kg 
every 3 weeks for four doses alone. Primary co-endpoints were PFS and OS 
(Larkin, Chiarion-Sileni, Gonzalez et al., 2015). Results from CheckMate 067 
demonstrated a statistically significant improvement in PFS in the combination 
therapy group and in the nivolumab alone vs ipilimumab alone. Median PFS was 
11.5 months in the nivolumab plus ipilimumab group versus 6.9 months in the 
nivolumab alone group versus 2.9 months for the ipilimumab alone group. Longer 
PFS was also seen in combination therapy and nivolumab alone group versus 
ipilimumab alone group across all subgroups of PD-L1, BRAF V600, and 
metastasis status (Larkin, Chiarion-Sileni, Gonzalez et al., 2015). In addition, the 
combination group and nivolumab monotherapy demonstrated higher ORR 
compared to ipilimumab alone with 50% and 40% versus 14% respectively. 
Importantly around 9% in each the combination and nivolumab monotherapy 
group had a complete response. In comparison, only 2% of the ipilimumab only 
group showed a complete response. Combination therapy-related adverse 
events included diarrhea, colitis, increased alanine aminotransferase and 
aspartate aminotransferase, while the most common monotherapy-related 
adverse events were diarrhea and fatigue (Larkin, Chiarion-Sileni, Gonzalez et 
al., 2015).  
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Non-small cell lung cancer (NSCLC) 
Lung cancer is one of the leading causes of death due to cancer, with non-small 
cell lung cancer (NSCLC) amounting for 80-85% of all lung cancer diagnoses 
(Siegel, Miller, Fuchs, Jemal, 2021). NSCLC subtypes include adenocarcinoma, 
squamous cell carcinoma and undifferentiated carcinoma and are grouped 
together due to their similarity in treatment and prognoses. Investigations into the 
characterization of NSCLC tumor microenvironments have revealed the 
categorization of NSCLC as “hot” tumors. The more immune infiltrate that is 
present, that is, the more “hot” a tumor is, the higher the expression in tumor and 
immune cells of pathways that regulate immune response such as PD-1 (Ferro, 
Huber, Rivoltini, 2018). This higher PD-1 expression is also often associated with 
better clinical efficacy in PD-1 blockade, making NSCLC a good target for 
immune checkpoint inhibitors. The standard of care for NSCLC has always been 
docetaxel which is a chemotherapy as second- or third-line treatment. However, 
chemotherapy treatment efficacy has always been counteracted by its toxicity 
and substantial side effects. In recent years, immune checkpoint inhibitors have 
emerged as an advance in the search for an effective therapy and have improved 






 On October 2, 2015, pembrolizumab was granted accelerated approval by the 
US FDA for treatment of patients with metastatic or advanced NSCLC based on 
the results of the KEYNNOTE-001 trial. Eligible patients had tumors that 
expressed PD-L1 and had disease progression even after treatment with 
chemotherapy or targeted therapy against epidermal growth factor receptor 
(EGFR). Positive PD-L1 tumors were determined through an FDA-approved 
immunohistochemistry test where PD-L1 strong, PD-L1 weak, or PD-L1 negative 
was determined based on the percentage of stained immune cells and calculated 
tumor proportion score (TPS) at greater than 50%, between 1% and 49%, and 
less than 1% respectively (Sul, Blumenthal, Jiang, He, Keegan, Pazdur, 2016). In 
this dose-escalation study, 550 patients were enrolled. Among them, 449 
patients had received prior treatment for NSCLC and 101 patients were 
treatment-naïve. Patients were treated either with 2 mg/kg of pembrolizumab 
every 3 weeks or 10 mg/kg of pembrolizumab every 2 or 3 weeks. The primary 
endpoints of the study were the evaluation of anti-tumor efficacy and 
characterization of the safety profile of pembrolizumab in NSCLC patients (Sul, 
Blumenthal, Jiang, He, Keegan, Pazdur, 2016). Out of the 61 patients who were 
determined to have PD-L1 strongly positive tumors, the ORR for those treated 
with 2 mg/kg was 28% compared to 41% in those treated with 10 mg/kg, which is 
evidence of a clinically significant magnitude of response. The most commonly 
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occurring adverse events were found in over 20% of the participant population 
and include fatigue, decreased appetite, cough, and dyspnea. The most common 
immune-related adverse events were thyroid disorders such as hyperthyroidism 
and hypothyroidism, as well as pneumonitis and colitis (Sul, Blumenthal, Jiang, 
He, Keegan, Pazdur, 2016). 
Hui, Gandhi, Costa, Felip, Ahn, Eder, et al published updated long-term OS data 
for the patients enrolled in KEYNOTE-001 for phase 1b in 2016. Compared to the 
previous study that calculated a cutoff TPS at less than 1%, 1-49%, and greater 
than 50%, this study assessed a PD-L1 positive expression as a staining cutoff of 
greater than 1% on tumor cells (Hui, Gandhi, Costa, Felip, Ahn, Eder et al., 
2016). Patients received either pembrolizumab 2 mg/kg or pembrolizumab 10 
mg/kg every 3 weeks or pembrolizumab 10 mg/kg every 2 weeks until disease 
progression or intolerable toxicity. With a TPS of less than 1%, the median OS 
was 22.1 months in treatment-naïve patients compared to 10.6 months for 
patients who had previously undergone treatment. The 18-month OS was 58% 
and 37%; 24-month OS was 44.5% and 31% respectively (Hui, Gandhi, Costa, 
Felip, Ahn, Eder et al., 2016). This OS data supports the efficacy of 
pembrolizumab long-term in NSCLC patients with PD-L1 positive expressing 
tumors.  
As both phases of KEYNOTE-001 produced reliable and durable responses in 
patients with advanced NSCLC, the study investigators sought to define a tumor 
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PD-L1 expression level that was associated with an increased likelihood of 
pembrolizumab treatment benefit. 495 patients were given either pembrolizumab 
2 mg/kg or 10 mg/kg every 3 weeks or 10 mg/kg every 2 weeks and were 
randomly assigned to either a training group or a validation group (Garon, Rizvi, 
Hui et al., 2015). The training group PD-L1 cutoff was defined as membranous 
PD-L1 expression in at least 50% of tumor cells, while the validation group PD-L1 
cutoff was selected by investigator review. The investigators found ORR to be 
45% in patients with PD-L1 expression greater than 50% including 50% in 
treatment-naïve groups and 44% in previously treated groups (Garon, Rizvi, Hui 
et al., 2015). The ORR for patients with a TPS of more than 50% was 
significantly higher than the patients with a TPS between 1% to 49% or less than 
1%. This data suggested the possibility of identification of patients with an 
increased likelihood to show response with pembrolizumab treatment. A TPS of 
at least 50% was associated with both a higher response rate and a longer 
progression-free survival compared to a TPS of less than 50% in both treatment-
naïve and previously treated groups (Garon, Rizvi, Hui et al., 2015). This 
suggests that this subgroup of NSCLC patients with a high PD-L1 expression 






On March 4, 2015, nivolumab became the first FDA approved immunotherapy 
drug for lung cancer. Although initially approved for the treatment of metastatic 
melanoma, based on the results from the CheckMate 017 trial, nivolumab 
approval was expanded to include patients with advanced NSCLC with disease 
progression during or after platinum-based chemotherapy treatment. Patients in 
this randomized phase 3 study had stage IIIB or IV squamous-cell NSCLC with 
disease recurrence after one prior treatment regimen of platinum-based 
chemotherapy (Brahmer, Reckamp, Baas, Crinò, Eberhardt, Poddubskaya et al., 
2015). 352 patients were enrolled and randomly assigned to receive intravenous 
nivolumab at 3 mg/kg every 2 weeks or docetaxel at 75 mg/m2 every 3 weeks. 
The primary endpoint of this study was OS and a crucial secondary endpoint 
included efficacy according to tumor PD-L1 expression of 1%, 5%, and 10%. PD-
L1 protein expression was determined before treatment with an 
immunohistochemical assay using PD-L1 staining on tissue samples obtained 
from patients. Samples were categorized as PD-L1 positive when staining 
reached prespecified levels of 1%, 5%, or 10% per 100 tumor cells (Brahmer, 
Reckamp, Baas, Crinò, Eberhardt, Poddubskaya et al., 2015). Investigators 
found OS of the nivolumab group to be higher compared to the docetaxel group, 
9.2 months versus 6 months, respectively. The OS rate of nivolumab-treated 
patients at 1 year was 42% compared to 24% in the docetaxel-treated patients 
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(Brahmer, Reckamp, Baas, Crinò, Eberhardt, Poddubskaya et al., 2015). The 
median PFS was also found to be higher, with the nivolumab group at 3.5 
months compared to 2.8 months in the docetaxel group. However, across the 
prespecified PD-L1 expression levels, the study did not find conclusive evidence 
suggesting the prognostic or predictive efficacy of nivolumab (Brahmer, 
Reckamp, Baas, Crinò, Eberhardt, Poddubskaya et al., 2015). This could be due 
to a lower prespecified PD-L1 expression level cutoff as compared to the study 
with pembrolizumab; it is likely that only tumors with strongly high expressing PD-
L1 can be considered predicative markers.  
On October 9, 2015, the FDA expanded approval of nivolumab to include 
metastatic nonsquamous NSCLC based on the results of the CheckMate 057 
trial. This phase 3 study enrolled patients with stage IIIB or stage IV or recurrent 
nonsquamous NSCLC that had progressed after either radiation therapy, surgical 
resection, or platinum-based doublet chemotherapy (Borghaei, Paz-Ares, Horn, 
Spigel, Steins, Ready et al., 2015). 582 patients were randomly assigned to 
receive intravenous nivolumab at 3 mg/kg every 2 weeks or docetaxel at 75 
mg/m2 every 3 weeks. Patients were followed for overall survival, which was 
found to be significantly longer with nivolumab treatment than docetaxel. 
Investigators saw a median OS of 12.2 months compared to 9.4 months 
respectively, representing a 24% lower risk of death when treated with nivolumab 
(Borghaei, Paz-Ares, Horn, Spigel, Steins, Ready et al., 2015). Even at 18 
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months, patients saw a higher OS rate with nivolumab treatment than docetaxel 
treatment, 39% to 23%, respectively. Interestingly, this study saw a predictive 
association between PD-L1 expression and clinical outcome at all expression 
levels with nivolumab treatment. This patient group was associated with longer 
OS and PFS as well as higher ORR as compared to docetaxel (Borghaei, Paz-
Ares, Horn, Spigel, Steins, Ready et al., 2015).  
 
Atezolizumab 
In 2016, a different type of inhibitor therapy appeared: PD-L1 inhibitors. If 
pembrolizumab and nivolumab block PD-1 interaction with PD-L1 to prevent 
dampening of the immune response, then would not blockade of PD-L1 
accomplish the same goal? The first PD-L1 inhibitor to be given FDA approval, 
Atezolizumab, was announced on October 18, 2016 for treatment in patients with 
previously treated metastatic NSCLC based on results from the POPLAR and 
OAK trials. Atezolizumab is a fully humanized IgG1 monoclonal antibody that 
binds to PD-L1 and blocks binding to PD-1, thus allowing the immune system to 
mount an anti-tumor response to activate and attack the tumor. Interestingly, by 
directly blocking PD-L1 as opposed to PD-1, atezolizumab still allows for the 
engagement of PD-1 with its lesser-known ligand PD-L2, which minimizes the 
probability of autoimmunity (Rittmeyer, Barlesi, Waterkamp et al., 2017). 
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The POPLAR trial is a phase 2 randomized trial that enrolled patients with 
disease progression after treatment with post-platinum chemotherapy. Patients 
were stratified based on PD-L1 tumor infiltrate status and randomly assigned to 
receive either intravenous Atezolizumab 1200 mg or docetaxel 75 mg/m2 every 3 
weeks (Fehrenbacher, Spira, Ballinger et al., 2016). PD-L1 tumor expression was 
graded using immunohistochemistry as TC3, TC2, TC1, and TC0, with 
percentages being greater than 50%, between 5% and 50%, between 1% and 
5%, and less than 1%, respectively (Fehrenbacher, Spira, Ballinger et al., 2016). 
The primary efficacy endpoint was to investigate overall survival in the patient 
population as well as in each of the PD-L1 tumor expression subgroups. With a 
minimum follow-up of 1 year, patients in the atezolizumab group had a 
significantly higher OS than docetaxel with the OS of the atezolizumab group 
being 12.6 months versus 9.7 months. Increased improvement in OS was also 
seen in PD-L1 tumor expression subgroups as the grades increased from TC0 to 
TC3, with TC3 having the highest OS out of all the groups (Fehrenbacher, Spira, 
Ballinger et al., 2016). Interestingly, only the group with the highest PD-L1 tumor 
expression, TC3, saw improved PFS and ORR compared to docetaxel 
(Fehrenbacher, Spira, Ballinger et al., 2016). Adverse events were noticeable 
higher in the docetaxel group with 39% of docetaxel patients experiencing 
treatment-related grade 3-4 adverse events compared with 11% of patients in the 
atezolizumab group (Fehrenbacher, Spira, Ballinger et al., 2016). This study 
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showed the superiority of Atezolizumab as a PD-L1 inhibitor compared to 
chemotherapy as well as proved the safety profile of the first PD-L1 inhibitor.  
The OAK trial is a phase 3 randomized trial which enrolled patients with stage 
IIIB or stage IV squamous or non-squamous NSCLC who had previously 
received up to two chemotherapy regimens. This was the first phase 3 trial of a 
PD-L1 antibody. A total of 850 patients were randomly assigned to receive either 
intravenous Atezolizumab 1200 mg or docetaxel 75 mg/m2 every 3 weeks. The 
coprimary endpoints included overall survival in the patient population as well as 
each of the PD-L1 subgroups (Rittmeyer, Barlesi, Waterkamp et al., 2017). The 
PD-L1 subgroups were determined in the same fashion as the POPLAR trial 
explained above. Overall survival was better with atezolizumab treatments in 
both the patient population and each of the PD-L1 expression subgroups. Median 
OS with atezolizumab was 13.8 months compared to docetaxel treatment at 9.6 
months (Rittmeyer, Barlesi, Waterkamp et al., 2017). However, similar to the 
POPLAR study above, both progression-free survival and objective response 
rate was similar between atezolizumab- and docetaxel-treated groups (Rittmeyer, 
Barlesi, Waterkamp et al., 2017). Also similarly, overall survival was seen 
throughout all the PD-L1 expression subgroups as compared to docetaxel. As 
expected, patients with the highest PD-L1 expression received the greatest 
benefit from atezolizumab treatment compared to docetaxel, 20.5 months versus 
9 months, respectively (Rittmeyer, Barlesi, Waterkamp et al., 2017). 
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Atezolizumab-related adverse events were reported in 64% of patients and were 
most commonly fatigue, decreased appetite, and nausea. Docetaxel-related 
adverse events were reported in almost all of the patients and were most 
commonly anemia, fatigue, neutropenia, and febrile neutropenia (Rittmeyer, 
Barlesi, Waterkamp et al., 2017). The results of this trial not only confirmed the 
results of the POPLAR trial, but also established high PD-L1 expression as an 




Breast cancer is the most common cancer affecting women in the United States 
and worldwide, with more than 284,000 cases and 44,000 deaths expected in 
2021 (Siegel, 2021). While there is a large percentage of patients who can be 
treated with a combination of local therapy such as surgery, radiation, or 
chemotherapy, 5-10% of all patients diagnosed with breast cancer have 
metastatic cancer and is still considered incurable (Planes-Laine, Rochigneux, 
Bertucci et al., 2019). Breast cancer can be divided into several subtypes, which 
are essentially characterized by the expression of human epidermal growth factor 
receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR), and 
are associated with assorted clinical outcomes and subtype-specific treatments 
(Planes-Laine, Rochigneux, Bertucci et al., 2019). Before the discovery of 
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immune checkpoint inhibitors, HER2-positive breast cancer patients benefitted 
from anti-HER2 treatments, ER/PR-positive breast cancer patients benefitted 
from endocrine therapy, and triple-negative breast cancer (TNBC) patients 
benefitted from chemotherapy. However, breast cancer has been unfortunately 
classified as a “cold” tumor as it is non-immunogenic. There have been recent 
studies demonstrating that presence of certain populations of immune infiltrates 
in the tumor are correlated with a better clinical outcome (Solinas, Gombos, 
Latifyan, Piccart-Gebhart, Kok, Buisseret, 2017). For example, presence of CD8+ 
T cells which can kill cancer cells is correlated with better prognosis while the 
presence of CD4+ regulatory T cells which regulate immune tolerance is 
associated with a poor prognosis (Solinas, Gombos, Latifyan, Piccart-Gebhart, 
Kok, Buisseret, 2017). The growing exploration into the role of immune infiltrates 
in previously non-immunogenic breast cancer has invigorated the development of 
new immunotherapies, including immune checkpoint inhibitors. TNBC is HER2-
negative, ER-negative, and PR-negative, giving rise to its name as triple-
negative, but this points to an unmet need in TNBC patients. The lack of HER2, 
estrogen, and progesterone receptor expression removes the possibility of other 
therapies, and their only approved systemic option is chemotherapy, which 





On November 13, 2020, the FDA gave pembrolizumab accelerated approval as a 
treatment in combination with chemotherapy for patients with recurrent local 
unresectable or metastatic triple-negative breast cancer whose tumors express 
PD-L1. This approval was based on the results of the KEYNOTYE-355 trial, but 
three separate trials (KEYNOTE-012 and -086) paved the way in showing a 
superiority using pembrolizumab monotherapy compared to chemotherapy alone.  
KEYNOTE-012 was the earliest trial performed investigating pembrolizumab 
monotherapy against TNBC in 2016. In this phase 1b nonrandomized trial, 32 
patients with TNBC expressing PD-L1 positive tumors were enrolled (Nanda, 
Chow, Dees et al., 2016). Some patients had received previous treatments while 
others were treatment-naïve. PD-L1 positive expression was defined as tumors 
with more than 1% staining seen in immunohistochemistry. Patients were given 
intravenous pembrolizumab at 10 mg/kg until disease progression or evident 
toxicity (Nanda, Chow, Dees et al., 2016). The primary efficacy endpoint was 
ORR with secondary endpoints of PFS, OS, and duration of response. In the 27 
patients who met the inclusion protocol for efficacy analysis based on RECIST 
1.1, the ORR was 18.5% with one patient experiencing complete response and 
four patients experiencing partial response (Nanda, Chow, Dees et al., 2016). 
15.6% of patients experienced at least one grade 3-5 adverse event including 
anemia, headache, and pyrexia (Nanda, Chow, Dees et al., 2016). Of note, the 
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patients included in this trial were heavily pre-treated and had received cancer 
therapy in both early-stage and advanced-stages. However, it is still important to 
note that this was the first published report showing antitumor activity in a TNBC 
patient population in clinic.  
In the phase 2 KEYNOTE-086 trial, two separate cohorts of patients with 
metastatic TNBC with no evidence of brain metastases were given 200 mg of 
intravenous pembrolizumab every 3 weeks for up to 2 years or until progressive 
disease or intolerable toxicity. In cohort A, all 170 enrolled patients had been 
previously treated with more than one systemic therapy and 60% of patients had 
PD-L1 positive tumors. Primary endpoints for this study included ORR in total 
and PD-L1 positive populations (Adams, Schmid, Rugo et al., 2019). In the total 
population, the ORR was 5.3% with two patients having a complete response 
and seven patients having a partial response. In the PD-L1 positive population, 
the ORR was 5.7% with two patients having a complete response and four 
patients having a partial response (Adams, Schmid, Rugo et al., 2019). The most 
common pembrolizumab-related adverse events in this study were fatigue and 
nausea and was experienced in 30% of patients. Immune-mediated adverse 
events occurred in 19% of patients and were hypothyroidism and 
hyperthyroidism. Of note, this patient population was also heavily pre-treated. On 
the other hand, in cohort B, patients were eligible only if they had no previous 
cancer therapy and also had to have a PD-L1 positive tumor. 84 patients were 
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enrolled with a primary endpoint of safety. There were no treatment-related 
adverse events above grade 3 and only 9% of patients experienced grade 3 
events (Adams, Loi, Toppmeyer et al., 2019). The most commonly experienced 
were fatigue, nausea, and diarrhea. Patients experienced an ORR of 21% with 
four patients having a complete response and fourteen patients having a partial 
response (Adams, Loi, Toppmeyer et al., 2019). Taken together, the results from 
these two cohorts suggest that pembrolizumab can act as a durable immune 
checkpoint immunotherapy in TNBC to activate antitumor activity with a better 
prognosis associated with earlier treatment and PD-L1 positive tumors.  
Most recently, the KEYNOTE-355 trial resulted in accelerated FDA approval for 
pembrolizumab in TNBC. Based on results of KEYNOTE-012 and KEYNOTE-
086 trials, it is known that pembrolizumab can show durable antitumor activity 
along with tolerable safety profiles in patients with metastatic TNBC. This trial 
aimed to show enhanced antitumor activity using pembrolizumab treatment in 
combination with chemotherapy (Cortes, Cescon, Rugo et al., 2020). In this 
randomized double-blind phase 3 trial, 847 patients were enrolled. Eligible 
patients had untreated recurrent inoperable metastatic TNBC with PD-L1 positive 
tumors and were assigned to either 200 mg of intravenous pembrolizumab every 
3 weeks with chemotherapy or placebo with chemotherapy. PD-L1 positive 
tumors were then separated in subtypes of TPS greater than 10, TPS between 1 
and 10, and TPS less than 1. Primary efficacy endpoints were median 
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progression-free survival (Cortes, Cescon, Rugo et al., 2020). In patients with 
TPS greater than 10, PFS was 9.7 months in the pembrolizumab with 
chemotherapy group compared to 5.6 months with the placebo and 
chemotherapy group. In patients with TPS between 1 and 10, PFS was 7.6 
months and 7.5 months in patients with TPS less than 1. Treatment efficacy in 
enrolled patients increased using pembrolizumab with increased PD-L1 
expression. Treatment-related adverse effects were also seen in both the 
pembrolizumab plus chemotherapy group and placebo plus chemotherapy group 
(Cortes, Cescon, Rugo et al., 2020).  
 
A novel approach: bispecific antibodies 
The invention of monoclonal PD-1 antibodies and monoclonal PD-L1 antibodies 
that have been approved as immune checkpoint inhibitors to block PD-1/PD-L1 
binding have revolutionized the cancer therapy landscape. Pembrolizumab, 
atezolizumab, durvalumab, avelumab, and others can treat a broad variety of 
cancer malignancies. Although these immunotherapies have significantly 
increased patient prognosis and clinical outcomes, there continues to be a 
subset of patients who are unable to receive long-term benefit or efficacy from 
these immunotherapies, leading to a need for alternative approaches. The 
clinical trials mentioned above have shown that PD-1 and PD-L1 monoclonal 
antibody inhibitors see an increased effect in patients with tumors of high PD-L1 
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expression. However, even in patients with tumors expressing high PD-L1, a 
portion of patients do not respond to these treatments, showcasing the need to 
improve on current therapies. As such, combination therapies have emerged 
based on the idea that additional mechanisms can be responsible for anti-PD-1 
therapy response failure. Accordingly, interest in bispecific antibodies for PD-1 
and PD-L1 have grown recently and they are now materializing as an innovative 
new class of immunotherapies that will further clinical efficacy. 
A bispecific antibody can be defined as two immunotherapies merging into one 
molecule that has the effect of both drugs (Dahlén, Veitonmäki, Norlén, 2018). 
Although development of a bispecific molecule is more complex and includes 
issues with stability and expression, bispecifics are attractive due to their dual 
targeting approach which can generate outcomes that cannot happen with 
monotherapies (Kotanides, Li, Malabunga et al., 2020). The argument for a 
bispecific that simultaneously blocks PD-1 and PD-L1 can be made. This 
bispecific could improve efficacy by enhancing tumor infiltrate, increasing T-cell 
activation, or facilitating bridging between PD-1 positive T cells and PD-L1 
positive tumor cells (Kotanides, Li, Malabunga et al., 2020). Two PD-1/PD-L1 
bispecifics look promising: one from a collaboration between Eli Lilly and 




Eli Lilly and Innovent 
IBI318 is a bispecific that is a human recombinant IgG1 bispecific antibody with 
Fc immune effector function that simultaneously targets PD-1 and PD-L1 
(Kotanides, Li, Malabunga et al., 2020). This antibody has been shown to restore 
T-cell activation and antitumor activity through its two arms: one arm blocks PD-
L1 from binding with PD-1 and the other arm blocks PD-1 from binding with PD-
L1 or PD-L2. IBI318 is expected to more completely inhibit the PD-1 pathway and 
improve efficacy through the formation of an immune synapse between T cells 
and tumor cells, thus bridging PD-1 and PD-L1 expressing cells (Kotanides, Li, 
Malabunga et al., 2020). Preclinical characterization data showed antitumor 
efficacy of IBI318 in humanized tumor xenograft mouse models, an experimental 
model in which human tumor tissue is implanted in mice with a fully intact human 
immune system to study the interaction more accurately between human immune 
cells and tumor cells in the lab. IBI318 treatment was shown to have enhanced 
activity over monoclonal PD-1 or PD-L1 antibodies in established lung and 
ovarian tumor cell lines (Kotanides, Li, Malabunga et al., 2020). This preclinical 
data propelled IBI318 to clinical trials, and preliminary results of the Phase 1a 
clinical study of the first bispecific PD-1/PD-L1 in patients with advanced tumors 
was presented on May 29, 2020. This study was meant to evaluate the safety 
profile and antitumor activity of the bispecific. Patients were given a dose 
escalation from 0.3 mg to 600 mg via accelerated titration to determine the safety 
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profile while a separate group was given IBI318 every 2 weeks. Of the patients 
receiving higher than 10 mg of IBI318, 30% had achieved a partial response. 
Preliminary results showed no patients experiencing grade 3 or higher treatment-
related adverse events. The study has now progressed to phase 1b, dose 
escalation phase (Xu, Zhao, Wei, Zhang, Wang, Wang et al., 2020).  
   
Compass Therapeutics 
Compass Therapeutics has also developed a common light chain-based 
bispecific tetravalent antibody targeting both PD-1 and PD-L1 through its binding 
arms. CTX-8371 was found through their StitchmabsTM bispecific screening 
platform and discovered that this bispecific was more potent than the 
combination of individual monoclonal antibodies. Preclinical evaluation of CTX-
8371 reported at a poster presentation showed increased potency of CTX-8371 
in vitro and in vivo compared to other clinical checkpoint monotherapies as well 
as the discovery of a unique mechanism of action. CTX-8371 was found to 
increase T cell activation and killing in vitro (Albu, 2019). Preclinical data also 
showed antitumor efficacy in several in vivo mouse models, most significantly 
TNBC and bladder cancers (p<0.0001 and p<0.001, respectively), as well as 
showing potent antitumor activity in mouse tumors in PD-1/PD-L1 humanized 
mice and human xenograft mouse models. In the humanized mice and xenograft 
mouse models, CTX-8371 was shown to outperform Keytruda (PD-1 
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monoclonal), Avelumab (PD-L1 monoclonal), and Keytruda in combination with 
Avelumab (PD-1 and PD-L1 monoclonal combination) in regard to tumor 
regression. Interestingly, it was discovered that a possible reason for the 
enhanced efficacy of CTX-8371 was a mechanism in which the bispecific causes 
large loss of PD-1 from the T cell surface, a mechanism that has not been seen 
in other bispecifics or monoclonal antibodies. This robust downregulation of PD-1 
from the T cell surface is mediated by bridging between T cell and tumor cell, 
providing a possible explanation of the ability of CTX-8371 to reverse PD-1 
suppression better than the standard immune checkpoint inhibitors (Albu, 2019).   
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CONCLUSIONS 
Cancer is a deadly group of diseases affecting a wide group of patients and 
caused by a variety of mechanisms. Throughout this paper, I have explored the 
major mechanisms for allowing uncontrollable cancer growth and subsequent 
disease progression, have focused on a single promising target for 
immunotherapies, and have summarized the major clinical studies targeting PD-1 
and PD-L1. I have also provided evidence for a novel bispecific antibody that 
could potentially more potently inhibit the PD-1 pathway for better treatment 
efficacy. 
Immunotherapy for cancer has made great strides in the last few years. 
Advancements in experimental investigations and drug engineering has allowed 
for the appearance of PD-1 and PD-L1 inhibitors, many of which have already 
gone through clinical trials and are approved for treatment in patients. Although 
there have been many early and accelerated FDA approvals for these 
monoclonal antibodies, some are stuck in Phase III confirmatory trials as they 
have failed to meet appropriate PFS and OS endpoints. The field of 
immunotherapy is still growing and has not yet reached its peak. Future 
immunotherapies offer great promise for cancer patients. The appearance of 
novel bispecifics such as CTX-8371 and their accompanying unique mechanism 
of action exemplifies the possibilities to come. CTX-8371 is the first immune 
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checkpoint inhibitor that is known to strongly downregulate PD-1, with 
subsequent potent antitumor efficacy in mouse models.  
However, serious investigation is required into several items. Although many 
patients have experienced success with PD-1 pathway treatments, there is a 
subgroup of patients who do not respond or only show a partial response. 
Furthermore, there is an increasing subset of patients who have an initial robust 
response to therapy but had to discontinue therapy during the clinical trials due to 
continuous disease progression. This suggests a need for further exploration into 
these patients, including mechanisms of possible resistance to PD-1 pathway 
treatments. Although these mechanisms are likely to be complex, as we continue 
to pour efforts into elucidating these pathways, improved treatments with far 
superior efficacy can be developed.  
Furthermore, an investigation into predictive biomarkers could elucidate a group 
of patients that would achieve benefit from these treatments. Although PD-L1 is 
the most likely answer, recent studies analyzing the usefulness of PD-L1 
expression as a predictive biomarker have found that this usefulness has not 
been clearly proven. Carretero-González, Lora, Martín Sobrino et al conducted a 
meta-analysis on clinical trials and concluded that PD-L1 expression in patients 
did not necessarily correlate with improved efficacy in cancer treatments. The 
clinical trials discussed in this paper also agree with this statement. Certain trials 
have seen improvement with PD-L1 positive treatments in PFS, but not in OS. 
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Therefore, PD-L1 expression cannot be considered a perfect biomarker for 
selecting patients for therapeutic strategies. This leaves the title of predictive 
biomarker empty and warrants further investigation.  
Additionally, the results of the clinical trials reviewed also call for further 
exploration of immune-related toxicity and adverse effects. The consequences of 
PD-1/PD-L1 blockade are worth a further look as knowledge of these associated 
toxicities are vital for these treatments to prioritize clinical safety and efficacy. 
Critics of the PD-1/PD-L1 blockade point to a prolonged activation of the immune 
system, which can lead to problems in autoimmunity as a main concern. These 
arguments warrant a further investigation to allow for continued improvements to 
these therapies.  
I hope these investigations can further progress and improved developments in 
the cancer immunotherapy landscape. Because there is such an intense focus 
on elucidating these pathways and mechanisms, it is possible that one 
breakthrough finding can introduce a new phase of immunotherapies to treat 
cancer. As we understand more about this disease, we will be equipped to 
design therapies that protect against the various ways a tumor can escape 
detection, which has already been done with the invention of PD-1 therapies. 
Further exploration and characterization of this PD-1 pathway treatment and 
related effects is clearly needed. 
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